Japan Vaccine-Production Improved Past Two Years, But Doubts Remain
This article was originally published in PharmAsia News
Executive Summary
Japan's capability of mass-producing a vaccine to stem a pandemic became a concern two years ago, leading to an effort that included Baxter International and Takeda Pharmaceutical to create a better system backed by government funding.